ABSTRACT
Several molecular and genomic biomarkers have been developed and validated to measure the internal dose and biologically effective dose of exposure to arsenic, to assess early biological effects of arsenic, to elucidate acquired and genetic susceptibility to arsenic-induced health hazards. These biomarkers are useful for the molecular dosimetry of arsenic exposure from various sources, the prediction and early detection of arsenic-induced diseases, the prevention or intervention of development of end-stage diseases caused by arsenic.
